Expert Interview
A second look: Discussing novel therapies in Graves' Disease with a focus on batoclimab and IMVT-1401 from Immunovant
Ticker(s): IMVT, ROIVInstitution: Stanford
- Assistant professor of ophthalmology at Stanford and Director of the Oculofacial plastic, Reconstructive surgery and Orbital Oncology Eyes Institute at the Byers Eye Institute at Stanford
- Specializes in aesthetic oculofacial surgery, thyroid eye disease and orbital oncology
- Research interests include the proteomic evaluation of ocular surface and orbital inflammation, modulation of neural reflexes via neurotization and neurostimulation and evaluating targeted therapies for cutaneous and orbital malignancies
How are you currently treating Graves' Disease patients?
Added By: wilson_adminHow optimistic on IMVT-1401 based on the existing data?
Added By: wilson_adminWhat other novel therapeutics for Graves' disease look interesting to you?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
